Aurubis, the Germany-based non-ferrous metal supplier, has announced its plan to invest a total of €330 million ($355.3 million) in precious-metal processing and environmental protection at its site in Hamburg. This investment is part of the company's efforts to expand its system for reducing emissions in primary copper production.
New Projects in Hamburg
Aurubis will allocate approximately €300 million for the establishment of a new precious metal processing plant at its Hamburg site. Additionally, the company will invest €30 million to further support environmental protection measures. With these two projects, Aurubis aims to enhance its capabilities in processing precious metals while contributing to the reduction of environmental impact.
Significant Total Investment
Together with previously approved initiatives, the current investments bring Aurubis' total investment in its Hamburg plant to an impressive €750 million. This highlights the company's commitment to growth and development in the region.
Expansion Plans Overseas
In addition to its investment in Hamburg, Aurubis plans to allocate €740 million for the construction of a new plant, Aurubis Richmond, located in the U.S. state of Georgia. Furthermore, the company aims to expand its existing solar park at a plant in Bulgaria.
These expansion projects demonstrate Aurubis' dedication to increasing its global presence and reinforcing its role as a leading player in the non-ferrous metal industry.
For more information, contact Aurubis.
Centene Corp. Sets Positive Guidance for 2024
Nvidia: The Leader in AI Computing
Related Articles
Stocks in Asia-Pacific Rise
Japanese shares declined, but stocks in Asia-Pacific mostly rose on Jan. 18. Hong Kong and China saw gains, while other markets had mixed performance.
Hunter Biden Requests Dismissal of Federal Gun Case
Hunter Biden requests dismissal of federal gun case, alleging political motivation and mishandling of evidence. Trial looms amidst political climate.
Revolution Medicines to Acquire EQRx in $1 Billion Deal
Revolution Medicines, a clinical-stage oncology company, is set to acquire EQRx in an all-stock deal worth $1 billion.